晶泰科技赋能国内首个“AI+RNA”小分子创新药获批临床试验

Core Viewpoint - ReviR, a company incubated by Jingtai Technology, has received approval from the National Medical Products Administration for clinical trials of RTX-117, a small molecule drug for Charcot-Marie-Tooth disease (CMT), set to begin in Q1 2026 [2] Group 1: Company Developments - RTX-117 is the first innovative Class 1 drug targeting CMT in China and marks the first clinical project from a series of rare disease drug pipelines developed through AI and robotic-assisted research [2] - Jingtai Technology will receive milestone payments and has the right to participate in sales revenue sharing and future licensing income from the RTX-117 pipeline [2] Group 2: Industry Insights - The economic constraints of traditional drug development have long limited breakthroughs in rare disease treatments, but AI-driven precision drug discovery is changing this paradigm [2] - The clinical progress of RTX-117 validates Jingtai's platform's rapid translation capability from algorithms to clinical applications, highlighting the significant potential of the AI+RNA research path in rare disease drug development [2] - The RTX-117 pipeline has previously received IND approval and orphan drug designation from the FDA, allowing it to benefit from priority review and extended market exclusivity in overseas markets [2]